The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab/nivolumab.
 
Vincent The-Luc Ma
No Relationships to Disclose
 
Stephanie Daignault
Consulting or Advisory Role - Boston Scientific
Research Funding - Bayer; Pfizer
 
Jessica Waninger
No Relationships to Disclose
 
Leslie Anne Fecher
Consulting or Advisory Role - Elsevier; Hoosier Cancer Research Network; Via Oncology
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Merck (Inst); Pfizer/EMD Serono (Inst)
(OPTIONAL) Uncompensated Relationships - NCCN
 
Michael Green
No Relationships to Disclose
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer
Speakers' Bureau - AstraZeneca
Research Funding - Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Harpoon Therapeutics (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Progenics (Inst); Progenics (Inst); Prometheus (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Christopher D. Lao
Consulting or Advisory Role - Bristol-Myers Squibb; Immunocore
Research Funding - Bristol-Myers Squibb; Dynavax Technologies; Genentech; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Immunocore